Zevra Therapeutics (NASDAQ:ZVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.28 EPS

Zevra Therapeutics (NASDAQ:ZVRA) issued its earnings results on Tuesday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28), Zacks reports. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $12.00 million during the quarter, compared to analyst estimates of $8.93 million.

Zevra Therapeutics Stock Performance

Zevra Therapeutics stock opened at $7.92 on Thursday. The company has a market cap of $422.74 million, a price-to-earnings ratio of -4.02 and a beta of 1.98. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The stock’s 50-day moving average is $7.95 and its 200-day moving average is $8.14.

Insider Buying and Selling

In other news, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the sale, the chief executive officer now owns 222,060 shares of the company’s stock, valued at $1,745,391.60. This represents a 21.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO R. Laduane Clifton sold 11,000 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the transaction, the chief financial officer now directly owns 51,361 shares in the company, valued at approximately $403,697.46. This represents a 17.64 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Guggenheim set a $21.00 target price on Zevra Therapeutics and gave the company a “buy” rating in a report on Tuesday, February 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Thursday. Finally, Canaccord Genuity Group dropped their target price on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $21.71.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.